KK2 - To be clear the deal with HL is in no way a CVR. It is just a licensing deal that allows HL to manufacture and distribute Apabetalone in China and the territories. The deal clearly spells out the remuneration to RVX based on certain sales levels achieved. Also to be clear this licensing deal is the largest single molecule deal ever done with a Chinese company up to that point. Assuming Apabetalone passes all trials required then the application process for each country that sales will be made in follows its own path. China as with any other country has its own path to be followed.

It is my understanding that the numbers on the charts used in past presentations do not include the sales in China. The large market opportunity lies in Europe and the USA. From what I have read the USA has the single largest spend per capita of any country in the world and represents roughly 50% of the world market. All of the rest of the world, including China, represents the remaining 50%(these are estimates). China has lots of people however many of those people have, by our standards, low income. As far as I have been able to determine there is no national health care system in China so buying drugs is an out of pocket expense for anyone who chooses to buy their medication.

Between taking care of the financing issue, getting FDA approval and passing the upcoming FA, IMO this stock could explode.

DYODD

tada